Scouting report · HELP
Michael I. Halstead
Ex-President of Intra-Cellular Therapies; Helus Pharma CEO since August 2026
- Born / age
- (53)
- Role
- Chief Executive Officer and Director
- In the role
- 2 mo
- Education
- BA Boston University
- Front Office rank
- not ranked yet
HELP
Stake value$2.3m168,568 shares · as of 21 Sep 2026
—thin record
Scouting sheetas of 24 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company five-year record: neutral — inherited: the five-year record is mostly a predecessor's
Pay design—tsr, time only
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
—Say-on-pay
—Airtime on calls
- Beat
- 0
- Met
- 0
- Missed
- 0
- Withdrawn
- 0
- Still open
- 0
- Answers on calls
- 0
- Questions dodged
- 0
- Dodges / 100 answers
- —
Personal and ownership data
What to weigh
Watch 3
- Arrived 2026-08-03 as the fourth person to run the company in eleven months, a few months before the Q4 2026 APPROACH Phase 3 readoutsrc
- 28.4% of votes withheld on his first election as director on 2026-09-22src
- His salary, bonus target and any sign-on terms are not disclosed in any document read; the circular pre-dates his first pay yearsrc
Pay
- Bonus pays on
- —
- Long-term award pays on
- 1,075,000 RSUs vesting in three equal annual instalments from 2027-08-03; 283,334 PSUs vesting in two tranches when the share price reaches set levelssrc
- Pay at risk not on file
- Pays on returns tsr, time only
- Shareholder vote not on file
- Pay vs profit not on file
Career
- 2026-08 – now
- 2024-03 – 2025-04Intra-Cellular Therapiessrc
President
Promoted 2024-03-19; the Helus release says he led the $14.6bn sale to Johnson & Johnson, which closed in April 2025 per PR-2026-08-18 - 2019-01 – 2024-03
- 2014-07 – 2018-12
- 2005-07 – 2013-12Warner Chilcott plcsrc
Leadership positions, finishing as SVP Corporate Development (corporate development, legal, HR)
Directed the $3bn purchase of Procter & Gamble's pharmaceutical business (2009) and the $8.5bn sale to Actavis (2013), per PR-2026-08-03
Undated in the sources
- Davis Polk & Wardwellsrc, Corporate associate, M&A group
Not located: January to July 2014 (between Warner Chilcott and Intra-Cellular) and April 2025 to August 2026 (after the J&J closing) not located in any source searched; the Davis Polk years are not dated
The promise ledger
No promise on the record yet: the research routine has not scored this company's guidance.
Background
- Other Trained as a lawyer; his career has been in legal, corporate development and general management, and Helus is his first CEO rolesrc
- Other Has brought in former Intra-Cellular colleagues: Regina Donohue as Chief People Officer and Suresh Durgam, Intra-Cellular's former CMO, to the Scientific Advisory Boardsrc
- Other Not independent as a director; resident in New Jersey, per the 2026 circularsrc
Sources9
- Filing Helus Pharma press release: appoints Michael Halstead as CEO (Ex-99.1 to 6-K, acc 0001062993-26-003976) · 2026-08-03
- Filing Cybin Inc. management information circular for the 2026 annual and special meeting, dated 2026-08-18 (Ex-99 to 6-K, acc 0001833141-26-000067) · 2026-08-18
- Filing Helus Pharma press release: Regina Donohue as Chief People Officer, Suresh Durgam to SAB (Ex-99.1 to 6-K, acc 0001833141-26-000061) · 2026-08-18
- Filing Helus Pharma press release: results of 2026-09-22 annual and special meeting (Ex-99.1 to 6-K, acc 0001833141-26-000081) · 2026-09-22
- Filing Form 3, Michael Halstead (reporting CIK 1521548), Chief Executive Officer (acc 0000912282-26-001277) · 2026-09-17
- Filing Form 4, Michael Halstead, open-market purchase 2026-09-21 (acc 0000912282-26-001293) · 2026-09-21
- Filing Cybin Inc. audited consolidated financial statements FY ended 2026-03-31 (Ex-99.2 to 40-F, acc 0001833141-26-000046) · 2026-06-29
- Filing Intra-Cellular Therapies DEF 14A 2024 (acc 0001628280-24-018986) · 2024-04-29
- Filing Intra-Cellular Therapies DEF 14A 2016 (acc 0001193125-16-564211) · 2016-04-28